<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acute rheumatic fever: Treatment and prevention</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acute rheumatic fever: Treatment and prevention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acute rheumatic fever: Treatment and prevention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Steer, MBBS, PhD, FRACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allan Gibofsky, MD, JD, FACP, FCLM</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert Sundel, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel J Sexton, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 09, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Acute rheumatic fever (ARF) is a nonsuppurative complication of pharyngeal infection with group A <em>Streptococcus</em> (GAS). Signs and symptoms of ARF develop two to three weeks following pharyngitis and include arthritis, carditis, chorea, subcutaneous nodules, and erythema marginatum [<a href="#rid1">1</a>].</p><p>Treatment and secondary prevention of rheumatic fever are reviewed here. Primary prevention (eg, treatment of streptococcal tonsillopharyngitis) and the epidemiology, pathogenesis, clinical manifestations, and diagnosis of ARF are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/8049.html" rel="external">"Treatment and prevention of streptococcal pharyngitis in adults and children"</a> and  <a class="medical medical_review" href="/d/html/3151.html" rel="external">"Acute rheumatic fever: Epidemiology and pathogenesis"</a> and  <a class="medical medical_review" href="/d/html/3177.html" rel="external">"Acute rheumatic fever: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H1567377786"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Treatment of ARF consists of antibiotic therapy, antiinflammatory therapy, heart failure management, and commencement of ongoing care (secondary prevention and provision of education) [<a href="#rid2">2-4</a>]. Hospitalization is advisable for optimal management of ARF, especially for an initial episode, so that all tests can be completed, response to therapy can be observed, and long-term preventative measures can be started with appropriate education for the patient and their caregivers.</p><p class="headingAnchor" id="H241072529"><span class="h2">Goals of treatment</span><span class="headingEndMark"> — </span>The six major goals of treatment are:</p><p class="bulletIndent1"><span class="glyph">●</span>Eradication of group A beta-hemolytic <em>Streptococcus</em> (GAS)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Symptomatic relief of acute disease manifestations (eg, arthritis, fever)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Manage rheumatic heart disease (RHD; eg, carditis, heart failure), if present</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Manage chorea, if present</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prophylaxis against future GAS infection to prevent progression of cardiac disease (see <a class="local">'Secondary prevention (antibiotic prophylaxis)'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Provision of education for the patient and patient's caregivers</p><p></p><p>There is no therapy that slows progression of valvular damage in the setting of ARF.</p><p class="headingAnchor" id="H3587246766"><span class="h2">Eradication of GAS carriage</span><span class="headingEndMark"> — </span>Patients with newly diagnosed ARF are started on antibiotic therapy to eradicate group A <em>Streptococcus </em>(GAS) carriage [<a href="#rid2">2</a>]. When a patient is diagnosed with ARF, they are presumed to have an associated GAS infection (typically pharyngitis, though pyoderma may also trigger ARF, particularly in tropical regions<em> </em>[<a href="#rid5">5</a>]<em>)</em>, even if GAS is not identified in culture. Thus, affected patients should receive prompt antibiotic therapy to eradicate GAS carriage, prevent ARF recurrences, and reduce the risk of developing RHD [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H3978620356"><span class="h3">GAS pharyngitis</span><span class="headingEndMark"> — </span>Treatment should proceed as delineated for management of GAS pharyngitis whether or not pharyngitis is present at the time of diagnosis  (<a class="graphic graphic_table graphicRef115983" href="/d/graphic/115983.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef64596" href="/d/graphic/64596.html" rel="external">table 2</a>). Treatment is given even if throat cultures are negative to ensure eradication of GAS that may persist in the upper respiratory tract. (See  <a class="medical medical_review" href="/d/html/8049.html" rel="external">"Treatment and prevention of streptococcal pharyngitis in adults and children", section on 'Antibiotic treatment'</a>.)</p><p>In practice, the most convenient and sensible approach is to administer long-acting intramuscular (IM) <a class="drug drug_general" data-topicid="9551" href="/d/drug information/9551.html" rel="external">penicillin G benzathine</a>, which serves two purposes:</p><p class="bulletIndent1"><span class="glyph">●</span>To eradicate GAS carriage</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As the first dose of secondary prophylaxis that is given every 21 to 28 days (see <a class="local">'Secondary prevention (antibiotic prophylaxis)'</a> below)</p><p></p><p>Oral alternatives, which should be used in the case of shortages of <a class="drug drug_general" data-topicid="9551" href="/d/drug information/9551.html" rel="external">penicillin G benzathine</a> [<a href="#rid6">6</a>] or in the case of penicillin allergy, are listed in the tables  (<a class="graphic graphic_table graphicRef115983" href="/d/graphic/115983.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef64596" href="/d/graphic/64596.html" rel="external">table 2</a>). These treatment options vary somewhat from those preferred for secondary prevention  (<a class="graphic graphic_table graphicRef138985" href="/d/graphic/138985.html" rel="external">table 3</a>). Penicillin allergy should be verified by history and ideally confirmed with testing by an allergy specialist if necessary before choosing an alternative to penicillin G benzathine. (See  <a class="medical medical_review" href="/d/html/2079.html" rel="external">"An approach to the patient with drug allergy"</a> and  <a class="medical medical_review" href="/d/html/16503.html" rel="external">"Penicillin skin testing"</a>.)</p><p>The efficacy of penicillin in this setting is supported by landmark controlled studies performed in the 1950s and 1960s that demonstrated dramatic reductions in rates of ARF and risk of ARF recurrence and/or complications in patients who were given prompt penicillin therapy [<a href="#rid7">7-9</a>]. It is also supported by decades of clinical experience [<a href="#rid2">2,3</a>].</p><p class="headingAnchor" id="H1155031177"><span class="h3">GAS pyoderma</span><span class="headingEndMark"> — </span>Patients from tropical and subtropical regions, in whom ARF may be triggered by group A <em>Streptococcus</em> (GAS) pyoderma, require antibiotic therapy, as for GAS pharyngitis, for streptococcal pyoderma. (See <a class="local">'GAS pharyngitis'</a> above and  <a class="medical medical_review" href="/d/html/7655.html" rel="external">"Impetigo", section on 'Treatment'</a> and  <a class="medical medical_review" href="/d/html/3151.html" rel="external">"Acute rheumatic fever: Epidemiology and pathogenesis", section on 'Role of Streptococcus pyogenes'</a>.)</p><p class="headingAnchor" id="H3343728646"><span class="h3">Household contacts</span><span class="headingEndMark"> — </span>Throat cultures (or evaluation for pyoderma if that was the GAS infection that identified the patient) should be performed on household contacts. Those with positive results should also receive a full course of antibiotic therapy, even if asymptomatic.</p><p class="headingAnchor" id="H2051605"><span class="h2">Arthritis management</span><span class="headingEndMark"> — </span>Antiinflammatory agents are the mainstay of symptomatic management of ARF-associated arthritis.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>First-line agents</strong> – For most patients with symptomatic ARF-associated arthritis, we suggest a nonsteroidal antiinflammatory drug (NSAID; eg, <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a>, <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a>) as the first-line antiinflammatory agent because NSAIDs have a lower risk of adverse effects compared with other agents (eg, <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, glucocorticoids). We typically use naproxen in this setting since it has the advantage of less frequent dosing. Dosing for naproxen is as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For children &gt;2 years old</strong> – 10 to 20 mg/kg/day in two divided doses given orally every 12 hours (maximum daily dose 1000 mg)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For adults</strong> – 250 to 500 mg twice daily (maximum daily dose 1250 mg)</p><p></p><p class="bulletIndent1">The efficacy of <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a> in this setting is supported by limited clinical trial data and observational studies [<a href="#rid10">10,11</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">Ibuprofen</a> has been used successfully in younger children with ARF, as was shown in one small observational study [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of treatment</strong> – NSAIDs are given as a standing dose until symptoms resolve and inflammatory markers have improved, provided the medication is well tolerated. Improvement is typically rapid (less than 48 hours) but occasionally may take one to two weeks, although longer courses (6 to 12 weeks) may be needed for persistent or rebound symptoms and elevated C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) [<a href="#rid13">13</a>]. (See <a class="local">'Monitoring'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternative agents</strong> – Alternatives to <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a> and <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Aspirin</strong> – <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">Aspirin</a> was historically the first-line antiinflammatory agent for ARF based upon extensive clinical experience [<a href="#rid14">14-16</a>]. However, limited clinical trial data and observational studies suggest that <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a> has similar efficacy with fewer adverse effects and less frequent dosing [<a href="#rid10">10,11</a>]. When aspirin is used in this setting, it is given at a starting dose of 50 to 60 mg/kg per day, up to 80 to 100 mg/kg/day in children and 4 to 8 g/day in adults, given in four to five divided doses.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Glucocorticoids</strong> – Low-dose glucocorticoids are a second-line option for patients who do not tolerate or are allergic to NSAIDs and/or <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of gastrointestinal toxicity</strong> – Patients taking NSAIDs for an extended duration (ie, several weeks) are at risk of developing gastrointestinal toxicity (eg, bleeding, ulcer).</p><p></p><p class="bulletIndent1">For pediatric patients taking <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a> or <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a>, prophylaxis is generally not necessary so long as the patient is otherwise well without any history of previous gastrointestinal upset with NSAIDs, gastroesophageal reflux disease, or bleeding diathesis.</p><p></p><p class="bulletIndent1">However, we do typically add a proton pump inhibitor (PPI; eg, <a class="drug drug_general" data-topicid="9718" href="/d/drug information/9718.html" rel="external">omeprazole</a>) if the patient develops gastrointestinal upset on an NSAID or an oral glucocorticoid. (See  <a class="medical medical_review" href="/d/html/35.html" rel="external">"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity", section on 'Proton pump inhibitors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrences</strong> – Resolution occurs in 90 percent within 12 weeks [<a href="#rid13">13</a>]. Recurrence of arthritis with reduction in the dose of antiinflammatory treatment most likely reflects the "rebound phenomenon" of ARF. This does not represent a recurrent episode of ARF, but rather that a longer course of treatment is required. Prolonged symptoms, especially in young females, should prompt diagnostic tests for systemic lupus erythematosus (SLE). (See  <a class="medical medical_review" href="/d/html/6420.html" rel="external">"Childhood-onset systemic lupus erythematosus (SLE): Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults"</a>.)</p><p></p><p class="headingAnchor" id="H831027637"><span class="h2">Carditis management</span><span class="headingEndMark"> — </span>The mainstays of management of rheumatic carditis are early diagnosis and assessment of severity using echocardiography, management of heart failure and other complications when present, and commencement of secondary antibiotic prophylaxis. Management of rheumatic carditis and valve disease in RHD are discussed in greater detail separately. (See <a class="local">'Secondary prevention (antibiotic prophylaxis)'</a> below and  <a class="medical medical_review" href="/d/html/114019.html" rel="external">"Management and prevention of rheumatic heart disease", section on 'Management of carditis in acute rheumatic fever'</a> and  <a class="medical medical_review" href="/d/html/114019.html" rel="external">"Management and prevention of rheumatic heart disease", section on 'Management of rheumatic heart disease'</a>.)</p><p class="headingAnchor" id="H3364150890"><span class="h2">Sydenham chorea management</span><span class="headingEndMark"> — </span>Sydenham chorea (SC) is generally self-limited, and most cases do not require treatment beyond the usual chronic antibiotic therapy to prevent recurrence of ARF and minimize the risk of RHD (see <a class="local">'Secondary prevention (antibiotic prophylaxis)'</a> below). Patients with significant impairment related to their chorea may be treated with chorea-suppressing medication and/or antiinflammatory treatment (ie, glucocorticoids). Referral to a child neurologist or movement disorder specialist can help guide management.</p><p>The management of SC is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/6228.html" rel="external">"Sydenham chorea", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H2052052"><span class="h2">Other</span><span class="headingEndMark"> — </span>The rash associated with ARF is temporary and does not require specific treatment, although antihistamines may help to alleviate pruritus.</p><p class="headingAnchor" id="H100643944"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>Measurement of C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) may be useful for monitoring the acute disease process. The CRP is probably more useful since it typically normalizes over a matter of days once an episode of acute inflammation has resolved, while the ESR may stay elevated for up to two months after a transient inflammatory stimulus. However, the susceptibility of this measurement to artefact and other causes of inflammation may limit its use for this purpose. This monitoring can be conducted by an experienced primary care clinician or ARF specialist.</p><p>We check CRP twice weekly initially and then every one to two weeks until levels have normalized off therapy. Normalization of inflammatory markers is an indication of resolution, whereas an increase as treatment is tapered suggests a rebound of inflammation. A normal result obtained a few weeks after discontinuing antiinflammatory therapy suggests that the course of the illness is complete (unless chorea appears).</p><p>Where access to laboratory investigations is constrained or not possible, response to treatment is judged by clinical response.</p><p class="headingAnchor" id="H2052695"><span class="h1">RISK FACTORS FOR RECURRENT DISEASE</span><span class="headingEndMark"> — </span>Several factors are associated with an increased risk of recurrent ARF, including [<a href="#rid2">2,17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Poor adherence to secondary prophylaxis and inadequate service delivery.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A greater number of previous attacks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A shorter time interval since the last attack.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A higher likelihood of ongoing exposure to streptococcal infections, which includes children, those in close contact with children (parents/caregivers, health care workers), and those living in crowded situations [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Younger age.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Presence of cardiac involvement. Patients who have had rheumatic carditis (with or without valvular disease) are at relatively high risk for recurrent carditis and are likely to sustain increasingly severe cardiac involvement with each recurrence [<a href="#rid19">19,20</a>].</p><p></p><p class="headingAnchor" id="H7"><span class="h1">PRIMARY PREVENTION</span><span class="headingEndMark"> — </span>Prevention of initial development of rheumatic fever (primary prevention) is accomplished by prompt diagnosis and antibiotic treatment of group A <em>Streptococcus</em> (GAS) tonsillopharyngitis and, in some settings, GAS pyoderma [<a href="#rid5">5,21,22</a>]. These issues are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6867.html" rel="external">"Evaluation of acute pharyngitis in adults"</a> and  <a class="medical medical_review" href="/d/html/8049.html" rel="external">"Treatment and prevention of streptococcal pharyngitis in adults and children"</a> and  <a class="medical medical_review" href="/d/html/5971.html" rel="external">"Group A streptococcal tonsillopharyngitis in children and adolescents: Clinical features and diagnosis", section on 'Diagnosis'</a>.)</p><p>Appropriate antibiotic treatment of pharyngitis prevents ARF in most cases [<a href="#rid7">7</a>]. However, at least one-third of ARF episodes occur in the setting of subclinical streptococcal infection [<a href="#rid23">23</a>]. In addition, ARF is not preventable in symptomatic patients who are not able to access medical care.</p><p class="headingAnchor" id="H8"><span class="h1">SECONDARY PREVENTION (ANTIBIOTIC PROPHYLAXIS)</span></p><p class="headingAnchor" id="H3069673593"><span class="h2">Rationale and efficacy</span><span class="headingEndMark"> — </span>Patients who have had an attack of ARF and develop subsequent group A <em>Streptococcus</em> (GAS) pharyngitis are at high risk for a recurrent attack of ARF. Rheumatic heart disease (RHD) becomes more severe with each recurrent episode. Thus, the most effective method to limit progression of RHD severity is prevention of recurrent GAS pharyngitis. We recommend long-term antimicrobial prophylaxis, rather than recognition and treatment of acute GAS pharyngitis episodes, because GAS infection does not need to be symptomatic to trigger a recurrent attack of ARF [<a href="#rid24">24</a>]. Long-term prophylaxis is warranted for patients with a well-documented history of ARF (including cases with Sydenham chorea [SC] as the sole manifestation), as well as those with definite evidence of RHD. Antibiotic prophylaxis is usually provided in the primary care setting rather than by tertiary care organizations and consulting cardiologists. (See  <a class="medical medical_review" href="/d/html/3177.html" rel="external">"Acute rheumatic fever: Clinical manifestations and diagnosis"</a>.)</p><p>During the course of prophylaxis, patients and their household contacts who develop acute episodes of GAS pharyngitis and/or pyoderma should be evaluated and treated promptly.</p><p>Although randomized trial data in patients with a known history of ARF are largely lacking, the efficacy of routine secondary prophylaxis in preventing disease progression is supported by observational data demonstrating substantially reduced rates of ARF recurrence and disease progression in the penicillin era compared with the pre-penicillin era [<a href="#rid18">18,25-27</a>]. Additional support comes from a study demonstrating considerably lower rates of GAS infection and recurrent ARF among patients treated with monthly <a class="drug drug_general" data-topicid="9551" href="/d/drug information/9551.html" rel="external">penicillin G benzathine</a> injections compared with intermittent oral <a class="drug drug_general" data-topicid="9751" href="/d/drug information/9751.html" rel="external">penicillin V</a> [<a href="#rid28">28</a>]. Secondary prophylaxis was also shown to decrease the risk of disease progression in a randomized trial of children aged 5 to 17 years in resource-limited settings diagnosed with latent RHD by population-wide screening and confirmatory echocardiograms [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/d/html/114019.html" rel="external">"Management and prevention of rheumatic heart disease", section on 'Secondary prevention'</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Antibiotic selection</span><span class="headingEndMark"> — </span>For most patients, we suggest long-acting <a class="drug drug_general" data-topicid="9551" href="/d/drug information/9551.html" rel="external">penicillin G benzathine</a> administered intramuscularly (IM) every 28 days rather than other regimens  (<a class="graphic graphic_table graphicRef138985" href="/d/graphic/138985.html" rel="external">table 3</a>). However, there is regional variation in use of penicillin G benzathine depending upon availability and cost. In regions where ARF is endemic, penicillin G benzathine continues to be the preferred agent since it is highly effective, low cost, and readily available.</p><p>By contrast, in nonendemic regions (eg, the United States and Europe), <a class="drug drug_general" data-topicid="9551" href="/d/drug information/9551.html" rel="external">penicillin G benzathine</a> is more costly, and recurrent shortages are a substantial and recurring problem [<a href="#rid6">6</a>]. Thus, oral agents (eg, <a class="drug drug_general" data-topicid="9751" href="/d/drug information/9751.html" rel="external">penicillin V</a>) are more commonly used in nonendemic compared with endemic regions.</p><p>Oral agents are also appropriate for patients with the following features:</p><p class="bulletIndent1"><span class="glyph">●</span>Proven penicillin allergy (where a macrolide such as <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> is used)</p><p class="bulletIndent1"><span class="glyph">●</span>Severe valvular disease from RHD due to increased risk for sudden death following IM injections</p><p class="bulletIndent1"><span class="glyph">●</span>Bleeding problems following injections that cannot be addressed</p><p class="bulletIndent1"><span class="glyph">●</span>Ongoing concerns regarding IM injections despite attempts to address them</p><p></p><p class="headingAnchor" id="H1782447937"><span class="h3">Parenteral prophylaxis</span><span class="headingEndMark"> — </span>The preferred parenteral antibiotic for prophylaxis is long-acting <a class="drug drug_general" data-topicid="9551" href="/d/drug information/9551.html" rel="external">penicillin G benzathine</a> administered IM  (<a class="graphic graphic_table graphicRef138985" href="/d/graphic/138985.html" rel="external">table 3</a>) [<a href="#rid2">2,30,31</a>]. Most patients are started on an every-28-day dosing regimen (dose of 600,000 units if ≤27 kg; 1.2 million units if &gt;27 kg). A shorter dosing interval (eg, administration every 21 days) may be appropriate for populations in which the incidence of ARF is particularly high. This approach is also warranted for persons in low-incidence regions who have had recurrent ARF despite adherence to a regimen administered every 28 days [<a href="#rid32">32</a>]. Barriers to injections should be identified and addressed in patients where service delivery is failing before switching to oral therapy.</p><p>Switching from IM to oral prophylaxis (eg, <a class="drug drug_general" data-topicid="9751" href="/d/drug information/9751.html" rel="external">penicillin V</a> 250 mg twice daily) once patients have reached young adulthood and have remained free of rheumatic attacks may be appropriate if antibiotic prophylaxis is continued and supply and low cost of oral penicillin can be assured. However, individual circumstances should be carefully considered, including frequency of exposure to population groups (eg, school-aged children and adolescents) that have a higher incidence of GAS pharyngitis.</p><p class="headingAnchor" id="H3185304926"><span class="h3">Oral prophylaxis</span><span class="headingEndMark"> — </span>Options for oral prophylaxis include <a class="drug drug_general" data-topicid="9751" href="/d/drug information/9751.html" rel="external">penicillin V</a>, macrolides, and <a class="drug drug_general" data-topicid="9960" href="/d/drug information/9960.html" rel="external">sulfadiazine</a>  (<a class="graphic graphic_table graphicRef138985" href="/d/graphic/138985.html" rel="external">table 3</a>). The preferred oral agent in patients without penicillin allergy is penicillin V (dose of 250 mg twice daily). <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">Amoxicillin</a> is used by some, but no published data are available on the efficacy of this antibiotic for secondary prophylaxis of ARF.</p><p>Success with oral prophylaxis depends on optimal service delivery and patient adherence, so clear communication regarding the importance of prophylaxis and how antibiotics should be taken is critical. Even with optimal service delivery and adherence, the risk of recurrence is higher in persons receiving oral prophylaxis than those receiving IM <a class="drug drug_general" data-topicid="9551" href="/d/drug information/9551.html" rel="external">penicillin G benzathine</a> [<a href="#rid25">25</a>]. This was illustrated in a controlled trial of 405 children and adolescents with rheumatic fever assigned to receive four weeks of IM penicillin G benzathine, oral <a class="drug drug_general" data-topicid="9749" href="/d/drug information/9749.html" rel="external">penicillin G</a> potassium, or oral <a class="drug drug_general" data-topicid="9960" href="/d/drug information/9960.html" rel="external">sulfadiazine</a>. In the first two years of the study, GAS infections recurred in 7, 20, and 24 percent of patients, respectively, and ARF recurred in 0, 4.8, and 2.7 percent of the patients, respectively. <a class="drug drug_general" data-topicid="9751" href="/d/drug information/9751.html" rel="external">Penicillin V</a> is now used rather than penicillin G because of its greater bioavailability (approximately 60 versus 30 percent, respectively) [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H4276722370"><span class="h3">Penicillin allergy</span><span class="headingEndMark"> — </span>Penicillin allergy should be verified by history and ideally confirmed with testing by an allergy specialist if indicated before choosing an alternative to <a class="drug drug_general" data-topicid="9551" href="/d/drug information/9551.html" rel="external">penicillin G benzathine</a>. Penicillin allergy is the most commonly reported drug allergy. However, most patients evaluated for this allergy have negative testing for IgE-mediated sensitivity, usually because they were inaccurately labeled as penicillin allergic or the allergy resolved over time. A macrolide (eg, <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> 6 mg/kg/day, maximum dose 250 mg) is usually the most appropriate agent for patients allergic to penicillin  (<a class="graphic graphic_table graphicRef138985" href="/d/graphic/138985.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/d/html/2079.html" rel="external">"An approach to the patient with drug allergy"</a> and  <a class="medical medical_review" href="/d/html/16503.html" rel="external">"Penicillin skin testing"</a>.)</p><p>The long-term benefits of IM <a class="drug drug_general" data-topicid="9551" href="/d/drug information/9551.html" rel="external">penicillin G benzathine</a> prophylaxis outweigh the risk of developing an allergic reaction since life-threatening allergic reactions are rare in patients who receive IM injections of penicillin [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H3545076829"><span class="h3">Severe valvular disease</span><span class="headingEndMark"> — </span>In patients with a history of ARF who have developed severe, symptomatic valvular disease (ie, mitral stenosis, aortic stenosis, aortic insufficiency), New York Heart Association class III or IV heart failure, or ventricular dysfunction (ie, ejection fraction &lt;50 percent), we recommend prophylaxis with an oral antibiotic rather than IM <a class="drug drug_general" data-topicid="9551" href="/d/drug information/9551.html" rel="external">penicillin G benzathine</a>  (<a class="graphic graphic_table graphicRef138985" href="/d/graphic/138985.html" rel="external">table 3</a>). This recommendation is based upon accumulating evidence of severe outcomes in a small number of patients and availability of a safe and effective alternative, as noted in an American Heart Association advisory following review of the data [<a href="#rid35">35</a>]. In patients who continue to receive IM penicillin G benzathine, measures can be taken to decrease the risk of cardiovascular compromise from a vasovagal reaction including reducing injection pain and related anxiety, ensuring the patient is well hydrated and fed, and administering the injection with the patient in the supine position.</p><p>Deaths occurring within hours of injection of <a class="drug drug_general" data-topicid="9551" href="/d/drug information/9551.html" rel="external">penicillin G benzathine</a> typically have been attributed to anaphylaxis [<a href="#rid34">34</a>]. However, on further review, many patients did not have signs and symptoms consistent with anaphylaxis and did not respond to appropriate therapy [<a href="#rid36">36</a>]. Limited observational data suggest that these patients died from cardiovascular compromise related to severe valvular disease [<a href="#rid7">7,37-39</a>]. The proposed mechanism is a physiologic response to the pain and/or fear related to the injection that triggers a vasovagal episode with hypotension, bradycardia, and syncope during or within minutes of administration. This is rapidly followed by decreased coronary perfusion, ventricular arrhythmia, and sudden death. These deaths primarily have occurred in younger patients with severe, symptomatic RHD. Those with symptomatic, severe mitral stenosis, particularly those with cachexia and decreased left ventricular systolic function (ejection fraction &lt;50 percent), followed by those with severe aortic stenosis and severe aortic insufficiency, appear to be at highest risk.</p><p class="headingAnchor" id="H405186091"><span class="h3">Breakthrough GAS pharyngitis on antibiotic prophylaxis</span><span class="headingEndMark"> — </span>Patients and their household contacts who develop symptoms suggestive of group A <em>Streptococcus</em> (GAS) pharyngitis while on antibiotic prophylaxis should be evaluated, including checking that they are receiving prophylaxis, and treated promptly. Patients with breakthrough GAS pharyngitis on penicillin should be treated with an alternative agent such as <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> for the acute episode and then restart penicillin prophylaxis  (<a class="graphic graphic_table graphicRef138985" href="/d/graphic/138985.html" rel="external">table 3</a>). Those on a 28-day dosing regimen of <a class="drug drug_general" data-topicid="9551" href="/d/drug information/9551.html" rel="external">penicillin G benzathine</a> should be switched to a 21-day regimen. Those on an oral antibiotic regimen may benefit from switching to IM penicillin G benzathine, particularly if adherence to the oral regimen is poor. (See  <a class="medical medical_review" href="/d/html/8049.html" rel="external">"Treatment and prevention of streptococcal pharyngitis in adults and children"</a>.)</p><p class="headingAnchor" id="H3943085809"><span class="h3">GAS pharyngitis in adults with a remote history of ARF</span><span class="headingEndMark"> — </span>In adults with a remote history of ARF who develop acute group A <em>Streptococcus</em> (GAS) pharyngitis and are no longer on prophylaxis, any of the GAS pharyngitis treatment options are reasonable  (<a class="graphic graphic_table graphicRef64596" href="/d/graphic/64596.html" rel="external">table 2</a>). Treatment is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/8049.html" rel="external">"Treatment and prevention of streptococcal pharyngitis in adults and children"</a>.)</p><p class="headingAnchor" id="H4034595455"><span class="h2">Duration</span><span class="headingEndMark"> — </span>Based upon limited evidence, secondary prevention for recurrent ARF consists of years of prophylactic antibiotic administration. The total duration depends upon risk of recurrent ARF and severity of disease. The duration of prophylaxis following ARF is outlined by severity category in the table  (<a class="graphic graphic_table graphicRef55223" href="/d/graphic/55223.html" rel="external">table 4</a>) [<a href="#rid2">2,40</a>]. In the setting of carditis, prophylaxis should continue until the patient is a young adult (21 years of age), which is usually approximately 10 years from the initial acute attack with no recurrence [<a href="#rid2">2,41,42</a>]. Antibiotic prophylaxis should continue even after valve surgery, including prosthetic valve replacement, because a recurrence of ARF can still affect perivalvular tissue, chordae, or another valve, with serious consequences.</p><p>Other patients may not require such lengthy duration of treatment. In a Chilean study of 59 patients with a history of ARF without carditis, prophylaxis was discontinued after five years or at age 18 years (whichever was longer) [<a href="#rid42">42</a>]. During 3349 patient-months of follow-up, only two ARF recurrences were observed (0.7 per 100 patient-years). These data suggest that ARF prophylaxis may be discontinued safely in young adults judged to be at low risk for recurrence who are maintained under careful prospective surveillance.</p><p>The risk for GAS exposure and severity of valvular disease should be reviewed upon reaching the end of a planned course for secondary prophylaxis. A decision regarding cessation or continuation of antibiotic prophylaxis should be made based upon individual clinical risks and benefits.</p><p class="headingAnchor" id="H1409578399"><span class="h2">Administration of parenteral prophylaxis</span><span class="headingEndMark"> — </span>Clinicians should recognize that minimizing the stress and pain of <a class="drug drug_general" data-topicid="9551" href="/d/drug information/9551.html" rel="external">penicillin G benzathine</a> injections is a key factor in patient willingness to continue with this therapy. Injecting penicillin G benzathine requires proper training and experience to lessen the pain [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H3087640197"><span class="h2">Case reporting and prevention programs</span><span class="headingEndMark"> — </span>Many countries require notification of all cases of ARF and RHD to the health authorities. Registration with a regional ARF/RHD prevention program with ongoing updating of all subsequent related clinical events is also recommended.</p><p class="headingAnchor" id="H3871471230"><span class="h2">Ongoing care</span><span class="headingEndMark"> — </span>Planning for ongoing care of the patient should begin during the admission and once the diagnosis is made. Coordination is required among health care teams involved in the care of the patient including specialists (eg, cardiologists), community care practitioners (eg, pediatricians, general practitioners, community nurses, and community health workers), and pharmacologic care practitioners. Frequency of appointments with specialty care teams will vary depending upon severity of RHD.</p><p class="headingAnchor" id="H800504200"><span class="h2">Education</span><span class="headingEndMark"> — </span>During an admission, it is crucial that patents and their caregivers receive adequate and culturally appropriate information and education about ARF and RHD [<a href="#rid44">44,45</a>]. The most crucial advice for patients is the importance of continuing secondary prophylaxis even though they will be mostly asymptomatic. There are a variety of resources available to track adherence to secondary prophylaxis, including mobile apps (eg, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.rhdaustralia.org.au%2Fapps&amp;token=bvhiNvboZByLg75vNseaJTANiyTIoQV2oE2MOag5JQHfRrjOAyDgQdt7LZ0rVcbT&amp;TOPIC_ID=3175" target="_blank">RHD Australia</a> and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ftakeheart.tv%2Ftake-heart-app%2F&amp;token=qOYil5PWr%2BboCBfuTs4t51PrdPZ6jpwFKhT2g4GJcfQzaGc0DPZP0nU%2FqmU8PbeX&amp;TOPIC_ID=3175" target="_blank">Take Heart</a>). In addition, it is essential to educate patients about the importance of treating sore throats early and recommending a nonpenicillin antibiotic (eg, <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a>) for this if the patient is taking penicillin prophylaxis.</p><p>Oral health is important in these patients because they are at high risk of developing infective endocarditis. Thus, patients should receive education about dental care. Patients with carditis should be encouraged to inform their doctor or dentist prior to any interventional procedure so that appropriate antibiotic prophylaxis can be given. A laminated card with the relevant details of the treatment can be helpful for patients and caregivers. (See  <a class="medical medical_review" href="/d/html/2147.html" rel="external">"Prevention of endocarditis: Antibiotic prophylaxis and other measures"</a>.)</p><p>Given the risks of ARF/RHD in pregnancy and labor, every female of childbearing age receiving secondary prophylaxis should also be given detailed family planning/contraception advice as an integral part of the education program. (See  <a class="medical medical_review" href="/d/html/8148.html" rel="external">"Acquired heart disease and pregnancy"</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">POSTSTREPTOCOCCAL REACTIVE ARTHRITIS</span><span class="headingEndMark"> — </span>Poststreptococcal reactive arthritis (PSRA) is a reactive arthritis that occurs after a symptom-free interval following group A <em>Streptococcus </em>(GAS) pharyngitis. Whether it is a separate entity from arthritis associated with ARF is controversial since PSRA can be difficult to distinguish from arthritis associated with ARF on clinical grounds. In addition, a small proportion of patients with PSRA have been observed to develop valvular heart disease [<a href="#rid46">46,47</a>]. (See  <a class="medical medical_review" href="/d/html/3177.html" rel="external">"Acute rheumatic fever: Clinical manifestations and diagnosis", section on 'Differential diagnosis'</a>.)</p><p>For this reason, some favor administering secondary prophylaxis to children from a low-risk group with suspected PSRA for one to two years after the onset of symptoms, although the efficacy of this approach is not well established [<a href="#rid2">2</a>]. Follow-up echocardiogram is done 12 to 24 months after instituting secondary prophylaxis. Evidence of valvular disease after one year should is evidence that the joint symptoms were manifestations of ARF and should lead to continued prophylaxis as outlined in the preceding sections. Antibiotic prophylaxis can be discontinued if a follow-up echocardiogram is normal.</p><p class="headingAnchor" id="H473726730"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110144.html" rel="external">"Society guideline links: Acute rheumatic fever and rheumatic heart disease"</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals of treatment </strong>– Treatment of acute rheumatic fever (ARF) consists of eradication of group A <em>Streptococcus</em> (GAS) infection with antibiotic therapy, symptomatic relief of arthritis with antiinflammatory therapy, management of heart failure and chorea if present, education, and commencement of secondary prevention. There is no therapy documented to slow progression of valvular damage in the setting of ARF. Measurement of inflammatory markers such as C-reactive protein (CRP) may be used to monitor resolution of the acute process. (See <a class="local">'Treatment'</a> above and <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Eradication of GAS carriage </strong>– For all patients with ARF, we recommend starting antibiotic therapy as delineated for eradication of streptococcal pharyngitis, whether or not pharyngitis is present at the time of diagnosis  (<a class="graphic graphic_table graphicRef115983" href="/d/graphic/115983.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef64596" href="/d/graphic/64596.html" rel="external">table 2</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). In practice, this is often best achieved by administration of a dose of intramuscular (IM) <a class="drug drug_general" data-topicid="9551" href="/d/drug information/9551.html" rel="external">penicillin G benzathine</a>, which also serves as the first dose of secondary prophylaxis. In addition, patients from tropical regions such as Northern Australia, in whom ARF may be triggered by GAS pyoderma, require the same antibiotic therapy as for GAS pharyngitis for any skin infections present. (See <a class="local">'Eradication of GAS carriage'</a> above and  <a class="medical medical_review" href="/d/html/7655.html" rel="external">"Impetigo"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Arthritis management </strong>– For patients with symptomatic ARF-associated arthritis, we suggest treatment with a nonsteroidal antiinflammatory drug (NSAID; eg, <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a>, <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a>) rather than other therapies (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). NSAIDs are given as a standing dose until symptoms resolve and inflammatory markers improve, provided the medication is well tolerated. Improvement is typically noted in one to two weeks. (See <a class="local">'Arthritis management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Carditis management </strong>– Management of carditis in patients with ARF is discussed separately. (See  <a class="medical medical_review" href="/d/html/114019.html" rel="external">"Management and prevention of rheumatic heart disease", section on 'Management of carditis in acute rheumatic fever'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chorea management </strong>– Sydenham chorea (SC) is generally self-limited, and most cases do not require treatment beyond the usual chronic antibiotic therapy to prevent recurrence of ARF and minimize the risk of RHD. Management of SC is reviewed separately. (See  <a class="medical medical_review" href="/d/html/6228.html" rel="external">"Sydenham chorea", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary prevention </strong>– Primary prevention is accomplished by prompt diagnosis and antibiotic treatment of GAS infection, as discussed separately. (See  <a class="medical medical_review" href="/d/html/8049.html" rel="external">"Treatment and prevention of streptococcal pharyngitis in adults and children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary prevention </strong>– We recommend chronic antimicrobial prophylaxis rather than no prophylaxis (ie, treating intermittently only if the patient develops a recurrent symptomatic acute GAS infection) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>)<strong>. </strong>The rationale for chronic therapy is to prevent subsequent episodes of GAS infection since both symptomatic and asymptomatic GAS infections can trigger recurrence of ARF, which in turn leads to development/progression of RHD. (See <a class="local">'Secondary prevention (antibiotic prophylaxis)'</a> above.)</p><p></p><p class="bulletIndent1">The choice of regimen is as follows  (<a class="graphic graphic_table graphicRef138985" href="/d/graphic/138985.html" rel="external">table 3</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Preferred regimen </strong>– For most patients, we suggest long-acting <a class="drug drug_general" data-topicid="9551" href="/d/drug information/9551.html" rel="external">penicillin G benzathine</a> administered IM every 28 days rather than other regimens (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). A 21-day regimen is appropriate if the patient has a breakthrough episode of ARF despite good adherence to the 28-day regimen. Penicillin G benzathine is widely available and inexpensive in endemic areas but may be costly or unavailable in nonendemic area. Thus, oral agents (eg, <a class="drug drug_general" data-topicid="9751" href="/d/drug information/9751.html" rel="external">penicillin V</a>) are more commonly used in nonendemic compared with endemic regions. (See <a class="local">'Antibiotic selection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Alternatives in select circumstances:</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In patients with severe, symptomatic valvular heart disease, heart failure, or ventricular dysfunction, we recommend prophylaxis with an oral antibiotic (usually <a class="drug drug_general" data-topicid="9751" href="/d/drug information/9751.html" rel="external">penicillin V</a>) rather than IM <a class="drug drug_general" data-topicid="9551" href="/d/drug information/9551.html" rel="external">penicillin G benzathine</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_3" rel="external">Grade 1C</a>). Oral agents are preferred because life-threatening cardiovascular events have been reported following IM injections in such patients.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Macrolides (eg, <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>) are an acceptable alternative for those with an allergy to penicillin.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duration of prophylaxis</strong> – The duration of antibiotic prophylaxis depends upon risk of recurrent ARF and severity of disease as summarized in the table  (<a class="graphic graphic_table graphicRef55223" href="/d/graphic/55223.html" rel="external">table 4</a>). (See <a class="local">'Duration'</a> above and <a class="local">'Risk factors for recurrent disease'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">RAMMELKAMP CH Jr, STOLZER BL. The latent period before the onset of acute rheumatic fever. Yale J Biol Med 1961; 34:386.</a></li><li><a class="nounderline abstract_t">Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2009; 119:1541.</a></li><li><a class="nounderline abstract_t">Webb RH, Grant C, Harnden A. Acute rheumatic fever. BMJ 2015; 351:h3443.</a></li><li class="breakAll">The 2020 Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease (3rd edition) https://www.rhdaustralia.org.au/arf-rhd-guideline.</li><li><a class="nounderline abstract_t">Parks T, Smeesters PR, Steer AC. Streptococcal skin infection and rheumatic heart disease. Curr Opin Infect Dis 2012; 25:145.</a></li><li class="breakAll">Bicillin-LA (benzathine penicillin G) shortage. http://www.cdc.gov/std/treatment/drugnotices/bicillinshortage.htm (Accessed on October 31, 2016).</li><li><a class="nounderline abstract_t">DENNY FW, WANNAMAKER LW, BRINK WR, et al. Prevention of rheumatic fever; treatment of the preceding streptococcic infection. J Am Med Assoc 1950; 143:151.</a></li><li><a class="nounderline abstract_t">MASSELL BF, STURGIS GP, KNOBLOCH JD, et al. Prevention of rheumatic fever by prompt penicillin therapy of hemolytic streptococcic respiratory infections; progress report. J Am Med Assoc 1951; 146:1469.</a></li><li><a class="nounderline abstract_t">Spinks A, Glasziou PP, Del Mar CB. Antibiotics for treatment of sore throat in children and adults. Cochrane Database Syst Rev 2021; 12:CD000023.</a></li><li><a class="nounderline abstract_t">Hashkes PJ, Tauber T, Somekh E, et al. Naproxen as an alternative to aspirin for the treatment of arthritis of rheumatic fever: a randomized trial. J Pediatr 2003; 143:399.</a></li><li><a class="nounderline abstract_t">Çetin İİ, Ekici F, Kocabaş A, et al. The efficacy and safety of naproxen in acute rheumatic fever: The comparative results of 11-year experience with acetylsalicylic acid and naproxen. Turk J Pediatr 2016; 58:473.</a></li><li><a class="nounderline abstract_t">Yılmaz M, Gürses D, Tükenmez G. The effectiveness and safety of ibuprofen and acetylsalicylic acid in acute rheumatic fever. Pediatr Int 2022; 64:e15133.</a></li><li><a class="nounderline abstract_t">Osowicki J, Carr JP, Steer AC. Rheumatic fever: The rebound phenomenon returns. J Paediatr Child Health 2018; 54:685.</a></li><li><a class="nounderline abstract_t">United Kingdom and United States Joint Report: The treatment of acute rheumatic fever in children. Cooperative clinical trial of ACTH, cortisone and aspirin. Circulation 1955; 11:343.</a></li><li><a class="nounderline abstract_t">ILLINGWORTH RS, LORBER J, HOLT KS, RENDLE-SHORT J. Acute rheumatic fever in children; a comparison of six forms of treatment in 200 cases. Lancet 1957; 273:653.</a></li><li><a class="nounderline abstract_t">BYWATERS EG, THOMAS GT. Bed rest, salicylates, and steroid in rheumatic fever. Br Med J 1961; 1:1628.</a></li><li><a class="nounderline abstract_t">The natural history of rheumatic fever and rheumatic heart disease. Ten-year report of a cooperative clinical trial of ACTH, cortisone, and aspirin. Circulation 1965; 32:457.</a></li><li><a class="nounderline abstract_t">BLAND EF, DUCKETT JONES T. Rheumatic fever and rheumatic heart disease; a twenty year report on 1000 patients followed since childhood. Circulation 1951; 4:836.</a></li><li><a class="nounderline abstract_t">Majeed HA, Yousof AM, Khuffash FA, et al. The natural history of acute rheumatic fever in Kuwait: a prospective six year follow-up report. J Chronic Dis 1986; 39:361.</a></li><li><a class="nounderline abstract_t">Gordis L, Lilienfeld A, Rodriguez R. Studies in the epidemiology and preventability of rheumatic fever. II. Socio-economic factors and the incidence of acute attacks. J Chronic Dis 1969; 21:655.</a></li><li><a class="nounderline abstract_t">Stollerman GH. Rheumatic fever. Lancet 1997; 349:935.</a></li><li><a class="nounderline abstract_t">STOLLERMAN GH. The use of antibiotics for the prevention of rheumatic fever. Am J Med 1954; 17:757.</a></li><li><a class="nounderline abstract_t">Dajani AS. Current status of nonsuppurative complications of group A streptococci. Pediatr Infect Dis J 1991; 10:S25.</a></li><li><a class="nounderline abstract_t">Veasy LG, Wiedmeier SE, Orsmond GS, et al. Resurgence of acute rheumatic fever in the intermountain area of the United States. N Engl J Med 1987; 316:421.</a></li><li><a class="nounderline abstract_t">FEINSTEIN AR, WOOD HF, EPSTEIN JA, et al. A controlled study of three methods of prophylaxis against streptococcal infection in a population of rheumatic children. II. Results of the first three years of the study, including methods for evaluating the maintenance of oral prophylaxis. N Engl J Med 1959; 260:697.</a></li><li><a class="nounderline abstract_t">Manyemba J, Mayosi BM. Penicillin for secondary prevention of rheumatic fever. Cochrane Database Syst Rev 2002; :CD002227.</a></li><li><a class="nounderline abstract_t">Tompkins DG, Boxerbaum B, Liebman J. Long-term prognosis of rheumatic fever patients receiving regular intramuscular benzathine penicillin. Circulation 1972; 45:543.</a></li><li><a class="nounderline abstract_t">FEINSTEIN AR, SPAGUOLO M, JONAS S, et al. PROPHYLAXIS OF RECURRENT RHEUMATIC FEVER: INEFFECTIVENESS OF INTERMITTENT "THERAPEUTIC" ORAL PENICILLIN. JAMA 1965; 191:451.</a></li><li><a class="nounderline abstract_t">Beaton A, Okello E, Rwebembera J, et al. Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart Disease. N Engl J Med 2022; 386:230.</a></li><li><a class="nounderline abstract_t">STOLLERMAN GH, RUSOFF JH. Prophylaxis against group A streptococcal infections in rheumatic fever patients; use of new repository penicillin preparation. J Am Med Assoc 1952; 150:1571.</a></li><li><a class="nounderline abstract_t">Broderick MP, Hansen CJ, Faix DJ. Factors associated with loss of penicillin G concentrations in serum after intramuscular benzathine penicillin G injection: a meta-analysis. Pediatr Infect Dis J 2012; 31:722.</a></li><li><a class="nounderline abstract_t">Parnaby MG, Carapetis JR. Rheumatic fever in indigenous Australian children. J Paediatr Child Health 2010; 46:527.</a></li><li><a class="nounderline abstract_t">Levison ME, Levison JH. Pharmacokinetics and pharmacodynamics of antibacterial agents. Infect Dis Clin North Am 2009; 23:791.</a></li><li><a class="nounderline abstract_t">Allergic reactions to long-term benzathine penicillin prophylaxis for rheumatic fever. International Rheumatic Fever Study Group. Lancet 1991; 337:1308.</a></li><li><a class="nounderline abstract_t">Sanyahumbi A, Ali S, Benjamin IJ, et al. Penicillin Reactions in Patients With Severe Rheumatic Heart Disease: A Presidential Advisory From the American Heart Association. J Am Heart Assoc 2022; 11:e024517.</a></li><li><a class="nounderline abstract_t">Marantelli S, Hand R, Carapetis J, et al. Severe adverse events following benzathine penicillin G injection for rheumatic heart disease prophylaxis: cardiac compromise more likely than anaphylaxis. Heart Asia 2019; 11:e011191.</a></li><li><a class="nounderline abstract_t">STEIGMANN F, SUKER FR. Fatal reactions to benzathine penicillin G. Report of three cases and discussion of contributory factors. JAMA 1962; 179:288.</a></li><li><a class="nounderline abstract_t">Berkovitch M, Ashkenazi-Hoffnung L, Youngster I, et al. Fatal and Near-Fatal Non-allergic Reactions in Patients with Underlying Cardiac Disease Receiving Benzathine Penicillin G in Israel and Switzerland. Front Pharmacol 2017; 8:843.</a></li><li><a class="nounderline abstract_t">Ali S, Karadawi N, Elhassan NB, et al. Patterns, outcomes and trends in hospital visits of un-operated and operated children with rheumatic heart disease in Sudan. Cardiovasc Diagn Ther 2019; 9:165.</a></li><li class="breakAll">World Health Organization. Rheumatic fever and rheumatic heart disease: report of a WHO expert consultation. Geneva. WHO, 20 Oct to 1 Nov, 2001. WHO Tech Rep Ser 2001; 923.</li><li><a class="nounderline abstract_t">Rammelkamp CH Jr. Epidemiology of streptococcal infections. Harvey Lect 1955- 1956; 51:113.</a></li><li><a class="nounderline abstract_t">Berrios X, del Campo E, Guzman B, Bisno AL. Discontinuing rheumatic fever prophylaxis in selected adolescents and young adults. A prospective study. Ann Intern Med 1993; 118:401.</a></li><li class="breakAll">http://www.rhdaustralia.org.au/administering-bicllin.</li><li class="breakAll">http://www.rhdaustralia.org.au/individuals-families.</li><li class="breakAll">http://www.heartfoundation.org.nz/your-heart/heart-conditions/rheumatic-heart-disease.</li><li><a class="nounderline abstract_t">CREA MA, MORTIMER EA Jr. The nature of scarlatinal arthritis. Pediatrics 1959; 23:879.</a></li><li><a class="nounderline abstract_t">Ahmed S, Ayoub EM, Scornik JC, et al. Poststreptococcal reactive arthritis: clinical characteristics and association with HLA-DR alleles. Arthritis Rheum 1998; 41:1096.</a></li></ol></div><div id="topicVersionRevision">Topic 3175 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14490142" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The latent period before the onset of acute rheumatic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19246689" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26175053" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Acute rheumatic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26175053" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Acute rheumatic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22327467" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Streptococcal skin infection and rheumatic heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22327467" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Streptococcal skin infection and rheumatic heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15415234" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prevention of rheumatic fever; treatment of the preceding streptococcic infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14850321" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Prevention of rheumatic fever by prompt penicillin therapy of hemolytic streptococcic respiratory infections; progress report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34881426" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Antibiotics for treatment of sore throat in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14517527" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Naproxen as an alternative to aspirin for the treatment of arthritis of rheumatic fever: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28621087" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The efficacy and safety of naproxen in acute rheumatic fever: The comparative results of 11-year experience with acetylsalicylic acid and naproxen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35704468" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The effectiveness and safety of ibuprofen and acetylsalicylic acid in acute rheumatic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29411467" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Rheumatic fever: The rebound phenomenon returns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Cooperative clinical trial of ACTH, cortisone and aspirin</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13476677" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Acute rheumatic fever in children; a comparison of six forms of treatment in 200 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13689614" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Bed rest, salicylates, and steroid in rheumatic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4284068" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The natural history of rheumatic fever and rheumatic heart disease. Ten-year report of a cooperative clinical trial of ACTH, cortisone, and aspirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14879491" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Rheumatic fever and rheumatic heart disease; a twenty year report on 1000 patients followed since childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3700577" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The natural history of acute rheumatic fever in Kuwait: a prospective six year follow-up report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5770432" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Studies in the epidemiology and preventability of rheumatic fever. II. Socio-economic factors and the incidence of acute attacks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9093263" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Rheumatic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13207157" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The use of antibiotics for the prevention of rheumatic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1945592" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Current status of nonsuppurative complications of group A streptococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3807984" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Resurgence of acute rheumatic fever in the intermountain area of the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13644570" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A controlled study of three methods of prophylaxis against streptococcal infection in a population of rheumatic children. II. Results of the first three years of the study, including methods for evaluating the maintenance of oral prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12137650" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Penicillin for secondary prevention of rheumatic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5012243" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Long-term prognosis of rheumatic fever patients receiving regular intramuscular benzathine penicillin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14238024" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : PROPHYLAXIS OF RECURRENT RHEUMATIC FEVER: INEFFECTIVENESS OF INTERMITTENT "THERAPEUTIC" ORAL PENICILLIN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34767321" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12990472" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Prophylaxis against group A streptococcal infections in rheumatic fever patients; use of new repository penicillin preparation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22481428" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Factors associated with loss of penicillin G concentrations in serum after intramuscular benzathine penicillin G injection: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20854325" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Rheumatic fever in indigenous Australian children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19909885" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pharmacokinetics and pharmacodynamics of antibacterial agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1674296" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Allergic reactions to long-term benzathine penicillin prophylaxis for rheumatic fever. International Rheumatic Fever Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35049336" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Penicillin Reactions in Patients With Severe Rheumatic Heart Disease: A Presidential Advisory From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31297163" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Severe adverse events following benzathine penicillin G injection for rheumatic heart disease prophylaxis: cardiac compromise more likely than anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13916598" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Fatal reactions to benzathine penicillin G. Report of three cases and discussion of contributory factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29209214" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Fatal and Near-Fatal Non-allergic Reactions in Patients with Underlying Cardiac Disease Receiving Benzathine Penicillin G in Israel and Switzerland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31143638" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Patterns, outcomes and trends in hospital visits of un-operated and operated children with rheumatic heart disease in Sudan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31143638" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Patterns, outcomes and trends in hospital visits of un-operated and operated children with rheumatic heart disease in Sudan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Epidemiology of streptococcal infections</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8439112" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Discontinuing rheumatic fever prophylaxis in selected adolescents and young adults. A prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8439112" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Discontinuing rheumatic fever prophylaxis in selected adolescents and young adults. A prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8439112" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Discontinuing rheumatic fever prophylaxis in selected adolescents and young adults. A prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8439112" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Discontinuing rheumatic fever prophylaxis in selected adolescents and young adults. A prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13645124" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The nature of scarlatinal arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9627020" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Poststreptococcal reactive arthritis: clinical characteristics and association with HLA-DR alleles.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
